NL8602960A - Humaan mangaansuperoxydedismutase cdna, expressie daarvan in bacterien en werkwijze voor het winnen van enzymatisch actief humaan mangaansuperoxydedismutase. - Google Patents
Humaan mangaansuperoxydedismutase cdna, expressie daarvan in bacterien en werkwijze voor het winnen van enzymatisch actief humaan mangaansuperoxydedismutase. Download PDFInfo
- Publication number
- NL8602960A NL8602960A NL8602960A NL8602960A NL8602960A NL 8602960 A NL8602960 A NL 8602960A NL 8602960 A NL8602960 A NL 8602960A NL 8602960 A NL8602960 A NL 8602960A NL 8602960 A NL8602960 A NL 8602960A
- Authority
- NL
- Netherlands
- Prior art keywords
- superoxide dismutase
- polypeptide
- human
- manganese superoxide
- analog
- Prior art date
Links
- 108010012715 Superoxide dismutase Proteins 0.000 title claims description 210
- 102000019197 Superoxide Dismutase Human genes 0.000 title claims description 206
- 241000282414 Homo sapiens Species 0.000 title claims description 137
- 238000000034 method Methods 0.000 title claims description 68
- 239000011572 manganese Substances 0.000 title claims description 50
- 229910052748 manganese Inorganic materials 0.000 title claims description 22
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 title claims description 15
- 230000014509 gene expression Effects 0.000 title claims description 12
- 230000002255 enzymatic effect Effects 0.000 title claims description 11
- 241000894006 Bacteria Species 0.000 title claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 96
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 96
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 96
- 210000004027 cell Anatomy 0.000 claims description 76
- 239000013612 plasmid Substances 0.000 claims description 59
- 239000002773 nucleotide Substances 0.000 claims description 48
- 125000003729 nucleotide group Chemical group 0.000 claims description 47
- 108090000623 proteins and genes Proteins 0.000 claims description 43
- 108020004414 DNA Proteins 0.000 claims description 42
- 102000004169 proteins and genes Human genes 0.000 claims description 39
- 230000001580 bacterial effect Effects 0.000 claims description 35
- 150000001413 amino acids Chemical class 0.000 claims description 34
- 241000588724 Escherichia coli Species 0.000 claims description 27
- 239000002299 complementary DNA Substances 0.000 claims description 21
- 239000006228 supernatant Substances 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 19
- 102000053602 DNA Human genes 0.000 claims description 18
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 17
- 239000004472 Lysine Substances 0.000 claims description 17
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 16
- 239000013587 production medium Substances 0.000 claims description 15
- 239000002609 medium Substances 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 238000010367 cloning Methods 0.000 claims description 13
- 239000008057 potassium phosphate buffer Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 235000011056 potassium acetate Nutrition 0.000 claims description 8
- 210000000056 organ Anatomy 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 238000000502 dialysis Methods 0.000 claims description 5
- 208000028867 ischemia Diseases 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 239000008366 buffered solution Substances 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 230000010410 reperfusion Effects 0.000 claims description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- 238000005571 anion exchange chromatography Methods 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 238000005277 cation exchange chromatography Methods 0.000 claims description 3
- 210000002421 cell wall Anatomy 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000010412 perfusion Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 239000012465 retentate Substances 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 2
- 235000011009 potassium phosphates Nutrition 0.000 claims description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 2
- 238000011176 pooling Methods 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 101000868115 Homo sapiens Superoxide dismutase [Mn], mitochondrial Proteins 0.000 description 30
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 8
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 7
- 229910002535 CuZn Inorganic materials 0.000 description 7
- 229910052802 copper Inorganic materials 0.000 description 7
- 239000010949 copper Substances 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 238000010276 construction Methods 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 239000013613 expression plasmid Substances 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000006137 Luria-Bertani broth Substances 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 210000003705 ribosome Anatomy 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000007323 disproportionation reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 0 CC(C1C2)*2CC1=C Chemical compound CC(C1C2)*2CC1=C 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000010750 Metalloproteins Human genes 0.000 description 1
- 108010063312 Metalloproteins Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101710144724 Superoxide dismutase [Fe] Proteins 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- BQBCIBCLXBKYHW-CSMHCCOUSA-N Thr-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])[C@@H](C)O BQBCIBCLXBKYHW-CSMHCCOUSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 101150017120 sod gene Proteins 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80109085A | 1985-11-22 | 1985-11-22 | |
| US80109085 | 1985-11-22 | ||
| US90705186A | 1986-09-12 | 1986-09-12 | |
| US90705186 | 1986-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8602960A true NL8602960A (nl) | 1987-06-16 |
Family
ID=27122291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8602960A NL8602960A (nl) | 1985-11-22 | 1986-11-21 | Humaan mangaansuperoxydedismutase cdna, expressie daarvan in bacterien en werkwijze voor het winnen van enzymatisch actief humaan mangaansuperoxydedismutase. |
Country Status (21)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610520B1 (en) * | 1985-11-22 | 2003-08-26 | Bio-Technology General Corp. | Gene encoding human manganese superoxide dismutase and recombinant polypeptide encoded thereby |
| JPS62215532A (ja) * | 1986-03-18 | 1987-09-22 | Ube Ind Ltd | 抗炎症剤 |
| JPH0643341B2 (ja) * | 1986-03-27 | 1994-06-08 | 宇部興産株式会社 | 臓器機能改善剤 |
| JPH0643340B2 (ja) * | 1986-09-03 | 1994-06-08 | 宇部興産株式会社 | 虚血性心疾患治療薬 |
| JPS6377822A (ja) * | 1986-09-18 | 1988-04-08 | Ube Ind Ltd | 臓器機能改善剤 |
| US6326003B1 (en) | 1986-10-14 | 2001-12-04 | Chiron Corporation | Manganese superoxide dismutase cloning and expression in microorganisms |
| ATE132902T1 (de) * | 1987-03-14 | 1996-01-15 | Boehringer Ingelheim Int | Humane mangan-superoxiddismutase (hmn-sod) |
| US5260204A (en) * | 1987-03-14 | 1993-11-09 | Boehringer Ingelheim International Gmbh | Human manganese superoxide dismutase (hMn-SOD) |
| EP0284105B1 (en) * | 1987-03-27 | 1995-11-15 | Bio-Technology General Corporation | Human manganese superoxide dismutase and methods of treatment |
| JPH01233228A (ja) * | 1988-03-11 | 1989-09-19 | Toyo Jozo Co Ltd | 悪性腫瘍細胞転移防止剤 |
| US5772996A (en) * | 1990-08-03 | 1998-06-30 | Public Health Laboratory Service Board | Pharmaceutical compositions containing superoxide dismutase from Bacillus Stearothermophilus and Bacillus Caldotenax |
| DE4038563A1 (de) * | 1990-12-04 | 1992-06-11 | Gruenenthal Gmbh | Verwendung von superoxiddismutasen zur prophylaxe und/oder behandlung von organversagen bei risikopatienten mit polytrauma |
| DE59310242D1 (de) * | 1992-09-09 | 2002-01-17 | Bio Technology General Corp | Verwendung von Mangan-Superoxiddismutase (Mn-SOD) zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen in niedriger Dosierung |
| DE4239877C1 (de) * | 1992-11-27 | 1994-03-17 | Boehringer Ingelheim Int | Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56102787A (en) * | 1980-01-18 | 1981-08-17 | Mamoru Sugiura | Preparation of human placenta superoxide dismutase |
| BG49718A3 (bg) * | 1983-07-15 | 1992-01-15 | Bio- Technology General Corp | Метод за получаване на полипептид със супероксиддисмутазна активност |
| DE3485284D1 (de) * | 1983-10-03 | 1992-01-02 | Chiron Corp | Klonieren von superoxid-dismutase und expression in mikroorganismen. |
-
1986
- 1986-10-29 IE IE285186A patent/IE59498B1/en not_active IP Right Cessation
- 1986-11-07 DK DK534686A patent/DK534686A/da not_active Application Discontinuation
- 1986-11-10 AU AU64975/86A patent/AU607897B2/en not_active Ceased
- 1986-11-13 GR GR862713A patent/GR862713B/el unknown
- 1986-11-14 SE SE8604884A patent/SE8604884L/xx not_active Application Discontinuation
- 1986-11-14 GB GB8627294A patent/GB2183658B/en not_active Expired - Fee Related
- 1986-11-18 ES ES8603083A patent/ES2003518A6/es not_active Expired
- 1986-11-19 AT AT0308986A patent/AT400443B/de not_active IP Right Cessation
- 1986-11-20 BE BE0/217445A patent/BE905796A/fr not_active IP Right Cessation
- 1986-11-20 IL IL80702A patent/IL80702A0/xx unknown
- 1986-11-20 IL IL10644986A patent/IL106449A/xx active IP Right Grant
- 1986-11-20 LU LU86676A patent/LU86676A1/fr unknown
- 1986-11-21 CA CA000523536A patent/CA1341362C/en not_active Expired - Lifetime
- 1986-11-21 CH CH4680/86A patent/CH676990A5/de not_active IP Right Cessation
- 1986-11-21 JP JP61278528A patent/JP2609449B2/ja not_active Expired - Lifetime
- 1986-11-21 FI FI864756A patent/FI90353C/fi not_active IP Right Cessation
- 1986-11-21 IT IT67865/86A patent/IT1205418B/it active
- 1986-11-21 DE DE3639725A patent/DE3639725C2/de not_active Expired - Fee Related
- 1986-11-21 NL NL8602960A patent/NL8602960A/nl active Search and Examination
- 1986-11-21 FR FR868616238A patent/FR2590591B1/fr not_active Expired
- 1986-11-21 PT PT83792A patent/PT83792B/pt not_active IP Right Cessation
-
1995
- 1995-05-18 HK HK75195A patent/HK75195A/xx not_active IP Right Cessation
-
1996
- 1996-01-22 JP JP8008627A patent/JP2967557B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3474190B2 (ja) | 合成ポリヌクレオチド | |
| NL8602960A (nl) | Humaan mangaansuperoxydedismutase cdna, expressie daarvan in bacterien en werkwijze voor het winnen van enzymatisch actief humaan mangaansuperoxydedismutase. | |
| EP0555649A2 (en) | Gene encoding transglutaminase derived from fish | |
| US5795776A (en) | Expression plasmids regulated by an OSMB promoter | |
| Beck et al. | Efficient production of active human manganese superoxide dismutase in Escherichia coli | |
| US4742004A (en) | Method for producing enzymatically active eucaryotic sod in bacteria | |
| WO2023051848A1 (zh) | 一种抗肿瘤重组胶原蛋白及其制备方法和应用 | |
| CN107746859A (zh) | 靶向血红蛋白hbb突变基因的造血干细胞基因修饰方法 | |
| CN117986355B (zh) | 一种重组人源化iii型胶原蛋白及其制备方法和用途 | |
| EP0284105B1 (en) | Human manganese superoxide dismutase and methods of treatment | |
| JP3462313B2 (ja) | 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体ｄｎａ及び変異型ウリカーゼの製造法 | |
| EP0483113B1 (en) | A method of producing an enzymatically active polypeptide analog of human Cu/Zn SOD | |
| US6361772B1 (en) | Human manganese superoxide dismutase DNA, its expression and method of recovering human manganese superoxide dismutase | |
| US5246847A (en) | Polypeptide analogs of human manganese superoxide dismutase and compositions and complexes thereof | |
| CN113453696A (zh) | 血红蛋白基因的编辑 | |
| Fujinaga et al. | Cloning and expression in Escherichia coli of the gene encoding the [2Fe-2S] ferredoxin from Clostridium pasteurianum | |
| US5270195A (en) | Plasmids for expression and method of producing a human manganese superoxide dimutase analog | |
| FR2550800A1 (fr) | Vecteur plasmide ameliore et son utilisation | |
| CN115873850A (zh) | 腺嘌呤碱基编辑系统及其应用 | |
| JPS60260522A (ja) | 遺伝子組換体が生産する生理活性物質の安定化法 | |
| CN114395585B (zh) | 用于碱基编辑的组合物 | |
| JP3491695B2 (ja) | Ｎ−アシルノイラミン酸アルドラーゼの製造法 | |
| JPH02219570A (ja) | ヒト５―リポキシゲナーゼの製造方法 | |
| JP2632680B2 (ja) | ブリ成長ホルモン構造遺伝子増幅プラスミド | |
| KR101124617B1 (ko) | 신규 리포산 합성효소와 리포산 단백질 리가제를 이용한 알파-리포산의 생산방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| BN | A decision not to publish the application has become irrevocable |